Aim: The aim of the present study was to evaluate the prevalence of metabolic syndrome among patients with epilepsy. Methods: This was a prospective study conducted and the participants were chosen from patients who attended an epilepsy outpatient clinic for 10 months. A total of 100 patients who met the study’s inclusion and exclusion criteria were chosen randomly. Results: The subjects consisted of 64 men and 36 women. Individuals aged 20 to 49 were selected as representatives of the demographic group with the least susceptibility to coronary artery disease and metabolic syndrome associated with ageing. 46% of the individuals fell between the age range of 20 to 29. Individuals in the age range of 30-39 accounted for 24% of the overall population, whilst those in the age range of 40-49 accounted for 30%. The average age of the participants was 33.7 years. Fifty patients (50%) were treated with monotherapy. Valproate was the predominant monotherapy treatment, representing 40% of patients. A substantial proportion of individuals with epilepsy were administered carbamazepine (24%) and phenytoin (18%) as monotherapy for seizure management. There was no discernible correlation between the length of time a person had epilepsy and the occurrence of metabolic syndrome. There was no correlation seen between the duration of therapy and the quantity of medications administered, as well as the occurrence of metabolic syndrome. A total of 40 patients were administered dual treatment. Ten individuals used polytherapy, which included the concurrent use of three or more drugs. Conclusion: Antiepileptic medicines, particularly valproate and carbamazepine, have notable impacts on the lipid profile and abdominal obesity in individuals undergoing therapy.